Watkins Thomas
Known title: DirectorCIK: 0001307935
Associated companies
Transaction History
| VNDA | ▲ Buy | Option Exercise | 15,000 | $62K | 6/2/2022 | View on chart |
| VNDA | ▼ Sell | Open Market | 6,441 | $64K | 6/2/2022 | View on chart |
| VNDA | ▲ Buy | Option Exercise | 15,000 | $62K | 6/2/2022 | View on chart |
| VNDA | ▼ Sell | Open Market | 6,441 | $64K | 6/2/2022 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Oppenheimer Launches Coverage on Vanda Pharmaceuticals
Oppenheimer has begun covering Vanda Pharmaceuticals, issuing an outperform rating and a $10 price target. The target sits near the middle of the analyst range and below the 52‑week high, suggesting a cautious upside view. The stock is trading above its $5.21 support level with an RSI of 41.6, indicating room for movement.
Oppenheimer Launches Coverage on Vanda Pharmaceuticals. Oppenheimer has begun covering Vanda Pharmaceuticals, issuing an outperform rating and a $10 price target. The target sits near the middle of the analyst range and below the 52‑week high, suggesting a cautious upside view. The stock is trading above its $5.21 support level with an RSI of 41.6, indicating room for movement.